Finn
LGND Biotechnology · Royalties · Biotech · Small cap · Thesis updated November 1, 2026

Filspari drives strong royalty growth while legal risks persist

01 Running thesis

New assets step up as legacy drugs fade

Ligand offers a leaner way to invest in biotech upside. It does not need to build large sales teams for every new drug. Instead, it owns royalty rights and gets paid when partner therapies reach patients.

The investment thesis strengthened in the third quarter of 2026 as royalty revenue surged 51 percent year over year to $70.3 million. More importantly, newer growth engines like Filspari finally overtook older assets like Kyprolis in total contribution. This validates management's strategy of deploying capital to outgrow incoming generic patent cliffs. The recent XOMA acquisition also adds massive diversification and tax benefits.

However, new scale brings new pressures. Older cash cows are already declining in sales, and generic competition for Evomela is a reality. Legal risks are also rising. Management expects litigation related to the XOMA deal, and Viking Therapeutics filed a formal cross-complaint in July 2026 over a canceled program.

Finn sees a complex transition. Business performance and growth are solid, but valuation scores suggest the market remains cautious. Ligand must now prove it can integrate XOMA cheaply, navigate legal challenges, and deploy its new capital wisely without overpaying.

Oct 2026▲Ligand reported a 51 percent year-over-year increase in third quarter royalty revenue, with Filspari overtaking Kyprolis as the largest single contributor.
Aug 2026→Ligand reported strong second quarter royalty growth and closed its XOMA acquisition, but warned of expected XOMA litigation and a formal cross-complaint from Viking Therapeutics.
May 2026▲Ligand announced a definitive agreement to acquire XOMA, which would add over 120 assets, and Filspari won FDA approval for FSGS. The update was tempered by Viking disputing Ligand's TR-Beta termination.
Feb 2026▲The 2025 Form 10-K confirmed 48 percent royalty growth for the year and positive Phase 3 data for Palvella's Qtorin rapamycin. It also showed large R&D funding outflows tied to new royalty deals.
Nov 2025▲Ligand raised about $445 million of net proceeds from convertible notes and third quarter royalties grew 47 percent year over year. The added cash supported the royalty acquisition strategy.
Aug 2025▲The Pelthos merger closed and ZELSUVMI launched, leaving Ligand with a 13 percent royalty and equity upside. Royalty revenue grew 57 percent year over year in the second quarter of 2025.
May 2025▲Ligand signed a definitive merger agreement for Pelthos and reported 44 percent royalty growth in the first quarter of 2025.
02 Business model

Collecting payments when partners win

Ligand makes money in three main ways: royalties on partnered drugs, sales of Captisol material, and contract revenue from milestone fees. Royalties are the core growth engine, reaching $70.3 million in the third quarter of 2026.

This model can be highly profitable. Ligand collects from many drug programs while keeping its own cost base small. The XOMA acquisition highlights this efficiency, with management expecting to run those new assets on less than $5 million in operating expenses.

The major tradeoff is control. Ligand does not run the drug trials or sales launches. If a partner struggles with a rollout or a drug faces generic competition, Ligand's cash flow falls even if its own team performed perfectly.

Capital allocation is the critical lever. Ligand relies on buying or funding royalty rights at attractive prices. With a large deployable capital base, the discipline to avoid overpaying for assets in the sub-$100 million deal market will define the company's next phase.

03 Product portfolio

A diversified royalty basket

Growth engine

Filspari

Travere's drug is approved for IgAN and FSGS. It generated an estimated $16.8 million in the third quarter of 2026, becoming Ligand's largest royalty asset.

Growth engine

XOMA royalty portfolio

The closed acquisition added over 120 assets to the mix, heavily diversifying the pipeline and adding exposure to Roche's Vabysmo.

Cash cow

Kyprolis and Evomela

These older royalties face generic pressure. Kyprolis sales continue to decline, and Evomela generics are actively entering the market.

Growth engine

Ohtuvayre

A newer asset driving strong top-line momentum following its launch by Merck for the maintenance treatment of COPD.

Steady

Captisol

Captisol is a drug solubility technology. Revenue is uneven because customer orders shift unpredictably between quarters.

Option

Qtorin rapamycin

A pipeline asset with Palvella. The FDA accepted the NDA for priority review, setting a target action date of February 28, 2027.

04 Business segments

Heavily weighted to royalties

Royalties83%growing fast
Captisol17%declining
Contract revenue and income0%declining

The mix uses Q1 2026 revenue categories for structural consistency. Royalties remain the undisputed primary revenue driver, exceeding $70 million in Q3 2026.

05 Risk factors

What could break the growth engine

Generic cliffs in older royalties

High impact · High odds

Royalty assets have finite lives. Kyprolis sales are falling, and Evomela faces generic competition. New assets must scale fast enough to replace this lost cash.

We watchQuarterly sales declines for Kyprolis and Evomela versus growth in new assets like Filspari.

Viking TR-Beta dispute escalation

High impact · Medium odds

Viking filed a cross-complaint in July 2026 alleging breach of contract after Ligand terminated the TR-Beta program. A negative outcome could result in high legal costs or lost economics.

We watchAny settlement or arbitration update regarding the VK2809 program cross-complaint.

XOMA litigation and integration

Medium impact · High odds

Management explicitly expects litigation in connection with the closed XOMA acquisition. The company also promised to run the new portfolio cheaply, a target that could be missed if integration falters.

We watchQuarterly operating expenses and legal fee disclosures related to XOMA.

Partner execution risk

High impact · Medium odds

Ligand depends on partners to win approvals and sell drugs. Delayed timelines, like Mirum's PSC submission pushing to 2027, defer expected returns.

We watchPartner updates on drug approvals, launch trajectories, and commercial sales figures.

Capital deployment discipline

High impact · Medium odds

Ligand has significant deployable capital. While this provides dry powder, having excess cash can tempt management to overpay for assets in a competitive market.

We watchTerms and return assumptions on new royalty purchases or funding commitments.
06 Quick answers

In one breath

What does Ligand Pharmaceuticals actually do?

Ligand owns rights to payments from drugs that other companies develop and sell. It also licenses technologies like Captisol, which helps make certain drugs easier to formulate.

Why is the XOMA acquisition important for Ligand?

XOMA added over 120 assets to Ligand's portfolio, instantly diversifying revenue. The deal also brought valuable tax attributes while testing management's integration skills.

Is Ligand a normal biotech company?

No. A normal biotech spends heavily to discover and sell its own drugs. Ligand operates more like a royalty owner, meaning partner success dictates its cash flow.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 1, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Ligand Q3 2026 Form 10-Q
  2. Ligand Q3 2026 Earnings Call Transcript
08 Explore the industry

Comparable Biotechnology companies

Companies near Ligand Pharmaceuticals Incorporated in Finn's Biotechnology industry ranking.

Get started with Finn today